1. HOME
  2. 業績

業 績

  1. Taguchi O., Tsujimura K., Kontani K., Harada Y., Nomura S., Ikeda H., Morita A., Sugiura H., Hayashi N., Yatabe Y., Tatematsu M., Takahashi T., Fukushima A. Behavior of bone marrow-derived cells following in vivo transplantation: Differentiation into stromal cells with roles in organ maintenance. Am. J. Pathol., 182: 1255-1262, 2013.
  2. Teramoto K, Ohshio Y, Fujita T, Hanaoka J, Kontani K. Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy. J Cancer Res. Clin. Oncol., 139 (5): 861-870, 2013.
  3. Ohshio Y, Teramoto K, Hashimoto M, Kitamura S, Hanaoka J, Kontani K. Inhibition of transforming growth factor-beta release from tumor cells reduces their motility associated with epithelial-mesenchymal transition. Oncol. Rep., 30: 1000-1006, 2013.
  4. Kontani K., Kuroda N., Hashimoto S., Murazawa C., Norimura S., Tanaka H., Ohtani M., Fujiwara-Honjo N., Kushida Y., Date M., Haba R., Houchi H., Yamauchi A., Yokomise H. Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer. Cancer Biol. Ther., 14(1):20-28, 2013.
  5. Kontani K., Hashimoto S., Murazawa C., Norimura S., Tanaka H., Ohtani M., Fujiwara-Honjo N., Date M., Houchi H., Yokomise H., Yamauchi A. Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more. Mol. Clin. Oncol., 1:225-230, 2013.
  6. Kontani K., Murazawa C., Norimura S., Yamashita K., Fujiwara-Honjo N., Ohtani M., Date M., Kushida Y., Muneuchi G., Haba R., Yokomise H., Yamauchi A. Indication for skin-sparing mastectomy with or without nipple preservation for primary breast cancer. Int. Surg., 95:12-20, 2010.
  7. Kuroda N, Kontani K, Kajikawa T, Taminato T. Study of the measurement of serum extracellular domain of HER2/neu protein with CLIA method. Rinsho Byori. 58(6): 541-552, 2010.
  8. Imachi H., Murao K., Dobashi H., Bhuyan MM., Cao X., Kontani K., Niki S., Murazawa C., Nakajima H., Kohno N., Yamashita H., Iwase H., Hayashi SI., Ishida T., Yamauchi A. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance. Breast Cancer Res Treat., 122(2):395-407, 2010.
  9. Nagahara K.., Arikawa T., Oomizu S., Kontani K., Nobumoto A., Tateno H., Watanabe K., Niki T., Katoh S., Miyake M., Nagahara S., Hirabayashi J., Kuchroo V., Yamauchi, A., Hirashima, M. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol., 181 (11): 7660-7669, 2008.
  10. Kontani K., Teramoto K., Ozaki Y., Sawai S., Tezuka N., Ishida H., Kajino K., Fujino S., Yamauchi A., Taguchi O., Kannagi R., Yokomise H., Ogasawara K. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody. Oncol Rep., 17(4): 895-902, 2007.
  11. Teramoto, K., Kontani, K., Fujita, T., Ozaki, Y., Sawai, S., Tezuka, N., Itoh, Y., Fujino, S., Taguchi, O., Kannagi, R., Ogasawara, K. Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analogue-loaded dendritic cells and tumor antigen DNA. Cancer Immunol. Immunother., 56(3): 331-342, 2007.
  12. Yamauchi A., Kontani K., Kihara M., Nishi N., Yokomise H., Hirashima M. Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer. Breast J. 12 Suppl 2:S196-200, 2006.
  13. Kontani, K., Kajino, K., Yamamoto, Y., Fujino, S., Taguchi, O., Yamauchi, A., Yokomise, H., Ogasawara, K. Spontaneous elicitation of potent anti-tumor immunity and eradication of established tumors by administration of DNA encoding soluble transforming growth factor-beta II receptor without active antigen-sensitization. Cancer Immunol. Immunother., 55(5):579-87, 2006.
  14. Huang CL, Liu D, Nakano J, Ishikawa S, Kontani K, Yokomise H, Ueno M. Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor--an expression in non-small-cell lung cancer. J. Clin. Oncol., 23(34): 8765-73, 2005.
  15. Dai, S.Y., Nakagawa, R., Itoh, A., Murakami, H., Kashio, Y., Abe, H., Katoh, S., Kontani, K., Kihara, M., Zhang, S. L., Hata, T., Nakamura, T., Yamauchi, A., Hirashima, M. Galectin-9 induces maturation of human monocyte-derived dendritic cells. J Immunol., 175(5):2974-81, 2005.
  16. Kihara, M., Kontani, K., Yamauchi, A., Miyauchi, A, Nakamura H., Yodoi, J., Yokomise, H. Expression of thioredoxin in patients with Graves’ disease. Int. J. Mol. Med., 15(5): 795-799, 2005.
  17. Kihara, M., Yamauchi, A., Kontani, K., Miyauchi, A, Yokomise, H. Recovery of parathyroid function after total thyroidectomy: Long-term follow-up study. ANZ J Surg., 75(7): 532-536, 2005.
  18. Irie, A., Yamauchi, A., Kontani, K., Kihara, M., Liu, D., Shirato, Y., Seki, M., Nishi, N., Nakamura, T., Yokomise, H., and Hirashima, M. Galectin-9 as a prognostic factor with anti-metastatic potential in breast cancer. Clin. Cancer Res., 11(8): 2962-2968, 2005.
  19. Kontani, K., Teramono, K., Ozaki, Y., Fujita, T., Tezuka, T., Sawai, S., Watanabe, H., Fujino, S., Yokomise, H., Ohkubo, I. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner. Int. J. Oncol., 25: 1537-1542, 2004.
  20. Ozaki, Y., Kontani, K., Teramono, K., Fujita, T., Tezuka, T., Sawai, S., Maeda, T., Watanabe, H., Fujino, S., Asai, T., Ohkubo, I. Involvement of 90 K / Mac-2 Binding Protein in Cancer Metastases by Increased Cellular Adhesiveness in Lung Cancer. Oncol. Rep., 12(5): 1071-7, 2004.
  21. Ozaki, Y., Kontani, K., Teramoto, K., Fujita, T., Tezuka, N., Sawai, S., Watanabe, H., Fujino, S., Asai, T., Ohkubo, I. Identification of Antigenic Epitopes Recognized by Mac-2 Binding Protein-specific Cytotoxic T Lymphocytes for the Use in Cancer Immunotherapy. Biochem. Biophys. Res. Commun., 317: 1089-1095, 2004.
  22. Kageyama, S., Isono, T., Iwaki, H., Wakabayashi, Y., Okada, Y., Kontani, K., Yoshimura, K., Terai, A., Arai, Y., Yoshiki, T. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin. Chem., 50 (5): 857-866, 2004.
  23. Kontani, K., Chano, T., Ozaki, Y., Tezuka, N., Sawai, S., Fujino, S., Saeki, Y. and Okabe, H. RB1CC1 suppresses cell cycle progression through RB1 expression in human neoplastic cells. Int. J. Mol. Med., 12(5): 767-769, 2003.
  24. Kontani, K., Taguchi, O., Sawai, S., Ozaki, Y., Hanaoka, J., Tezuka, N., Inoue, S., Fujino, S. Dendritic Cell Vaccine Immunotherapy of Cancer Targeting MUC1 Mucin. Int. J. Mol. Med., 12(4): 493-502, 2003.
  25. Teramoto, K., Kontani, K., Taguchi, O., Ozaki, Y., Sawai, S., Tezuka, N., Nagata, T., Koide, Y., Itoh, Y., Fujino, S., Asai, T., Ogasawara, K., Ohkubo, I. DNA Encoding a Pan-MHC Class II Peptide Analogue Augmented Antigen-specific Cellular Immunity and Suppressive Effects on Tumor Growth Elicited by DNA Vaccine Immunotherapy. Cancer Res., 63: 7920-7925, 2003.
  26. Teramoto, K., Chano, T., Ozaki, Y., Tezuka, N., Sawai, S., Kontani, K., Fujino, S., Okabe, H. Expression of RB1CC1, a novel tumor suppressor gene, is inversely correlated with the Ki-67 proliferation index in primary breast cancers. Cancer Ther., 1: 103-107, 2003.
  27. Chano, T., Kontani, K., Teramoto, K., Okabe, H., Ikegawa, S. Truncating mutations of RB1CC1 in human breast cancer. Nat Genet., 31(3):285-8, 2002.
  28. Kontani, K., Taguchi, O., Sawai, S., Ozaki, Y., Hanaoka, J., Tezuka, N., Inoue, S., Fujino, S., Maeda, T., Itoh, Y., Ogasawara, K., Sato, H., Ohkubo, I., Kudo, T. Novel vaccination protocol consisting of injecting MUC1 DNA and non-primed dendritic cells at the same region greatly enhanced MUC1-specific anti-tumor immunity in a murine model. Cancer Gene Ther., 9(4): 330-337, 2002.
  29. Chano, T., Ikegawa, S., Kontani, K., Okabe, H., Baldini, N., Saeki, Y. Identification of RB1CC1, a novel human gene that can induce RB1 in various human cells. Oncogene, 21(8):1295-8, 2002.
  30. Hanaoka J, Inoue S, Fujino S, Kontani K, Sawai S, Tezuka N, Ozaki Y, Teramoto K, Kashima H. Mediastinal cavernous hemangioma in a child: report of a case. Surg Today, 32(11):985-8, 2002.
  31. Ozaki, Y., Kontani, K., Hanaoka, J., Chano, T., Teramoto, K., NTezuka, N., Sawai, S., Fujino, S., Yoshiki, T., Okabe, H., Ohkubo, I. Expression and Immunogenicity of a Tumor-associated Antigen, 90K/Mac-2 Binding Protein, in Lung Cancer: The Possibility of its Clinical Use as a Tumor Marker and a Target Antigen in Cancer Immunotherapy. Cancer, 95: 1954-1962, 2002.
  32. Kontani, K., Taguchi, O., Narita, T., Izawa, M., Hiraiwa, N., Zenita, K., Takeuchi, T., Murai, H., Miura, S., Kannagi, R. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Br. J. Cancer, 84 (9): 1258-1264, 2001.
  33. Kontani, K., Sawai, S., Hanaoka, J., Ichinose, M., Tezuka, N., Inoue, S., Fujino, S. Involvement of Granzyme B and Perforin Produced by Tumor-Infiltrating Lymphocytes in Suppressing Metastasis of Cancer Cells to Regional Nodes in Patients with Breast and Lung Cancers. Eur. J. Surg. Oncol., 27: 180-186, 2001.
  34. Hanaoka, J., Kontani, K., Sawai, S., Ozaki, Y., Tezuka, N., Inoue, S., Fujino, S., Ohkubo, I. Analysis of MUC4 Mucin Expression in Lung Carcinoma Cells and its Immunogenicity. Cancer, 92(8): 2148-2157, 2001.
  35. Kontani, K., Taguchi, O., Narita, T., Hiraiwa, N., Sawai, S., J. Hanaoka, Ichinose, M., Tezuka, N., Inoue, S., Fujino, S., Kannagi, R. Autologous Dendritic Cells or Cells Expressing Both B7-1 and MUC1 Can Rescue Tumor-Specific Cytotoxic T Lymphocytes From MUC1-Mediated Apoptotic Cell Death. J. Leukocyte Biol., 68: 225-232, 2000.
  36. 法村 尚子、本城 尚美、香川 福宏、橋本 新一郎、村澤 千沙、伊達 学、金地 裕幸、大谷 昌裕、小笠原 豊、山内 清明、横見瀬 裕保、紺谷 桂一、術前乳腺MRIにより予定術式が変更された乳癌症例の検討:画像と病理診断が一致した5症例、乳癌の臨床、26(1): 67-73, 2011
  37. 仲田 洋美、橋本 新一郎、村澤 千沙、法村 尚子、紺谷 桂一、横見瀬 裕保、山城 千珠、柳原 敏宏、秦 利之、安田 真之、久保井 徹、日下 隆、大橋 育子、大久保 賢介、伊藤 進 妊娠初期に診断された乳がんの治療例 腫瘍内科、6(2): 153-158, 2010.
  38. 三好 信寛、澤口 和宏、増田 彰、山内 清明、横見瀬 裕保、紺谷 桂一 温度応答性培養皿を用いたOK-432誘導成熟樹状細胞培養法の確立 Biotherapy. 22(5): 339-343, 2008.
  39. 山内 清明、大水 総一、有川 智博、加藤 茂樹、法村 尚子、村澤 千紗、紺谷桂一、平島 光臣 ガレクチン9によるIL-17の制御とその意義 臨床免疫・アレルギー科. 49 (6): 690−697, 2008.
  40. 山内 清明、永原 慶子、大水 総一、延本 篤也、有川 智博、加藤 茂樹、法村 尚子、紺谷桂一、平島 光臣 樹状細胞の成熟とガレクチン9 臨床免疫・アレルギー科. 49 (2): 210−216, 2008.
  41. 山内 清明、紺谷桂一、曹 雪源、山下 啓子、河野 範男、岩瀬 弘敬 タモキシフェン効果予知因子としてのメニンの有用性 乳癌の臨床. 22 (5): 442-443, 2007.
  42. 紺谷桂一、森奈津実、中野淳、垂水晋太郎、井貝仁、三崎伯幸、後藤正司、中嶋尊、桝屋大輝、劉大革、石川真也、山本泰通、横見瀬裕保 癌抗原MUC1ムチンを標的とした活性化自己リンパ球移入療法:転移再発肺癌に対する治療 日本呼吸器外科学会雑誌. 19 (5): 634-640, 2005.
  43. 紺谷桂一、小笠原一誠. 転移再発癌患者からの活性型成熟樹状細胞誘導法 Biotherapy, 19(4): 339-346, 2005.
  44. 山内 清明、Shu-Yan Dai, 中川 竜介、阿部 博子、加藤 茂樹、紺谷桂一、平島 光臣 糖鎖結合蛋白ガレクチン9による樹状細胞成熟化日本臨床免疫学会誌. 28: 381−388, 2005.
  45. 紺谷桂一、寺本 晃治、尾崎良智、藤田 琢也、手塚則明、澤井聡、石田 英明、梶野 喜一、藤野昇三、小笠原 一誠. 超成熟樹状細胞誘導法の確立と誘導樹状細胞を用いた癌ワクチン免疫療法の開発. 消化器と免疫、41: 29-33, 2004.
  46. 紺谷桂一、寺本 晃治、尾崎良智、手塚則明、澤井聡、阿部 元、花澤 一芳、藤野昇三. 癌抗原90K/Mac-2 Binding Protein特異的HLA-A24拘束性細胞障害Tリンパ球の誘導とCTLエピトープの同定. 乳癌基礎研究会雑誌、12: 11-15, 2003.
  47. 寺本 晃治、紺谷桂一、尾崎良智、澤井聡、手塚則明、藤野昇三. チトクロームc由来TヘルパーペプチドDNAによる腫瘍抗原DNAワクチン増強効果. 乳癌基礎研究会雑誌、12: 55-60, 2003.
  48. 紺谷桂一、澤井聡、尾崎良智、花岡淳、手塚則明、井上修平、藤野昇三. 癌抗原MUC1を標的としたDNAワクチン療法の開発:マウスモデルを用いた検討. 乳癌基礎研究会雑誌、10: 70-73, 2001.
  49. 紺谷 桂一、澤井 聡、花岡 淳、小池 雅人、井上 修平、藤野 昇三 進行再発乳癌患者に対する癌免疫療法の試み 滋賀医科大学雑誌 16: 67, 2001.
  50. 花岡 淳、紺谷 桂一、澤井 聡、井上 修平、藤野 昇三、大久保 岩男 肺癌におけるMUC4ムチン発現の解析 滋賀医科大学雑誌, 16: 17-26, 2001.紺谷桂一、澤井聡、花岡淳、井上修平、藤野昇三. 癌抗原MUC1ムチンを標的とした樹状細胞ワクチン療法:進行再発乳癌を中心に. 癌の臨床、46(8), 961-965, 2000.
  51. 紺谷桂一、澤井聡、花岡淳、井上修平、藤野昇三. DCと癌抗原MUC1. Surgical Frontier, 17(2); 76-78, 2000.